Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DuPont Merck

Executive Summary

First year sales exceed projections by more than 10%, to $780 mil. Worldwide pharmaceutical sales contributed $634 mil., while the radiopharmaeuticals division reported revenues of $146 mil. The company also said it generated "respectable profits," despite costs involved in expanding European operations. Two "major" research compounds are "well into" Phase III clinicals -- Aviva (linopirdine) for treatment of Alzheimer's disease, and Avastar, (DUP-753) an antihypertensive being codeveloped with Merck.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS020479

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel